Hem › Magsäckscancer › North Carolina
Kliniska studier för Magsäckscancer i North Carolina
21 studier för Magsäckscancer söker deltagare vid platser i North Carolina.
Städer i North Carolina
Officiell studietext (engelska)
The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
RekryterarFriska volontärer välkomna
Ålder 45 till 75 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06995898Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
RekryterarFriska volontärer välkomna
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT07283939Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Rekryterar
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT07059884Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- och 6 fler
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 40 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05334069A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- University of North Carolina Medical Center, Chapel Hill
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07221149Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT07360314A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07213791Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 18 sep. 2026 · NCT05267626Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Charlotte
- Research Site, Wilmington
- Research Site, Winston-Salem
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT07431281Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT06750185A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Duke Cancer Institute, Durham
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT06253871A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Duke Cancer Institute, Durham
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 sep. 2026 · NCT07070232A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 6 aug. 2026 · NCT07749586Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #131, Raleigh
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 23 juli 2026 · NCT06974110Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 19 till 110 · Alla kön · Uppdaterad 29 juni 2026 · NCT02012699Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Duke Cancer Institute /ID# 276267, Durham
- Carolina BioOncology Institute /ID# 232597, Huntersville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 23 juni 2026 · NCT05005403A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 21 jan. 2026 · NCT07317505A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Huntersville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 7 jan. 2026 · NCT06999187SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 28 okt. 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2025 · NCT05107674APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- University of North Carolina, Chapel Hill
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 27 juni 2025 · NCT03175224Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.